Supporting Clinical Research in Dementia & Related Disorders

Advancing Scientific Innovation in Dementia & Related Disorders

With vast expertise in dementia and related disorders, VeraSci supports clinical trials from Lewy Body (LBD), Frontotemporal (FTD), Parkinson’s Disease and Vascular Dementias to Alzheimer’s Disease. Complex neurodegenerative diseases, like Alzheimer’s disease, affect multiple brain systems over the lifespan and require a multifaceted treatment strategy. Fortunately, there are now a number of promising agents in various stages of clinical development. The formula for therapeutic success in each of these is identifying the right target, using the right compound for the right stage of disease, within the right patient population, administered at the right dose, and employing the right clinical endpoints that are reliable, robust, and fit for purpose.

Our highly experienced team brings decades of clinical research and treatment experience to support state-of-the art clinical trials across a broad range of neurodegenerative disorders. We offer comprehensive start-to-finish services for clinical trials including trial design and regulatory strategy consultation, novel method development, implementation of rigorous assessment and quality assurance procedures, linguistics for multi-national trials, and interpretation of trial results.

 

Alexandra Atkins, PhD

 

VP, Scientific Development

 

Kathleen Anne Welsh-Bohmer, PhD, ABPP

VP, Neurodegenerative Disorders

 

Antonio Hernandez, PsyD

 

Senior Clinical Director, Neurodegenerative Disorders

Dependable Solutions for Global Clinical Trials

VeraSci is not just there in the beginning; we take care of your study objectives and data throughout the entire trial. As your partner, we leverage experience gained through hundreds of trials and ensure the highest quality data, all while anticipating any issues that can derail or delay your study before they arise.

 

We provide expert solutions in:

Select Endpoints & Assessments for Dementia & Related Disorders

Clinical

ADCS CGIC- AD Cooperative Study Clinician’s Global Impression of Change
C-SSRS- Columbia Suicide Severity Rating Scale
CDR- Clinical Dementia Rating Scale
CGIS- Clinical Global Impressions – Severity of Illness
GDS- Geriatric Depression Scale
NPI- Neuropsychiatric Inventory

Functional

ADCS ADL- Alzheimer’s Disease Cooperative Study Instrumental Activities of Daily Living Inventory
FAQ- Functional Activities Questionnaire

PRO

CFI- Cognitive Functioning Instrument
EQ-5D-5L- EuroQol-Five Dimensions
IQCOE- Informant Questionnaire on Cognitive Decline in the Elderly
NPI-Q- Neuropsychiatric Inventory Questionnaire
PGIC- Patient Global Impression of Change
QoL-AD- Quality of Life-Alzheimer’s Disease
RUD-Lite- Resource Utilization in Dementia
ZCI-AD- Zarit Caregiver Interview-Alzheimer’s Disease

Cognitive

ADAS-Cog- Alzheimer’s Disease Assessment Scale-Cognitive Subscale
BNT- Boston Naming Test
BVMT-R- Brief Visuospatial Memory Test – Revised
CDT- Clock Drawing Test
CERAD Battery- Consortium to Establish a Registry for Alzheimer’s Disease
CVLT-II- California Verbal Learning Test
Digit Span
DSST- Digit Symbol Substitution Test
FCSRT- Free and Cued Selective Reminding Test
HVLT-R- Hopkins Verbal Learning Test – Revised
Lexical Fluency
MiNT- Multilingual Naming Test
MMSE- Mini-Mental State Exam
MoCA- Montreal Cognitive Assessment
NTBNeuropsychological Test Battery
PACC Battery- Preclinical Alzheimer Cognitive Composite
REY-AVLT- Rey Auditory Verbal Learning Test
Semantic Fluency
Symbol Coding
TMT-A & B- Trail Making Test A & B
vADAS-cog- Vascular Alzheimer’s Disease Assessment Scale – Cognitive Subscale
Verbal Fluency
WAIS-III- Digit Span Forward and Backward